What Is the Fasting-Mimicking Diet and How Does It Work?

The fasting-mimicking diet (FMD) is a low-calorie, plant-based eating plan designed to trigger the same cellular responses as a water-only fast while still allowing you to eat food. A typical cycle lasts five to seven days and provides roughly 800 to 1,100 calories per day, with the calories carefully distributed among fats, carbohydrates, and a deliberately low amount of protein. The idea is to trick your body’s nutrient-sensing pathways into behaving as if no food is coming in, switching on protective and regenerative programs that evolved to help organisms survive periods of scarcity. Research over the past decade, mostly from Valter Longo’s lab at the University of Southern California and a growing number of independent groups, suggests the approach can improve metabolic markers, reduce biological age, and promote tissue regeneration in ways that simple calorie restriction does not.

The Basic Protocol

An FMD cycle is not a permanent change to your diet. You eat a restricted, specially formulated meal plan for a set number of days, then return to your normal eating pattern until the next cycle. Most published studies use cycles of four to seven days, repeated once a month or once every few months. The commercially available version (ProLon, developed by Longo’s team) runs five days. Research protocols have tested variations: one trial provided 850 calories per day over seven days, with one group getting only 10 percent of energy from protein and the other getting 30 percent, to study how macronutrient ratios affect the metabolic response.¹ In all versions, protein is kept low relative to a typical Western diet, and the food is plant-based, rich in unsaturated fats, and low in sugar.

The “mimicking” part is what distinguishes this from ordinary calorie restriction. The specific macronutrient profile, particularly the low protein content, is what keeps insulin and growth-factor signaling suppressed. If you simply ate 800 calories of steak and cheese, you would not get the same downstream cellular effects, because protein (and especially certain amino acids) activates the very growth pathways the FMD is designed to quiet.

What Happens Inside Your Cells

When you eat normally, your body runs primarily on glucose, and circulating levels of insulin, insulin-like growth factor 1 (IGF-1), and leptin stay relatively high. These hormones and growth factors tell your cells to grow, divide, and store energy. The FMD suppresses all three. With IGF-1 and insulin low, a cascade of intracellular signaling pathways that normally promote cell growth gets turned down. At the same time, protective programs ramp up: cells activate stress-resistance genes and longevity-associated transcription factors.²

Simultaneously, your body shifts its fuel source. Blood glucose drops, and cells begin breaking down fatty acids and producing ketone bodies for energy. This metabolic switch is a key part of the picture: the drop in glucose combined with the suppression of IGF-1 reduces the activity of a central nutrient-sensing hub called mTOR, which integrates signals about food availability and directs cells to either grow or conserve.³ When mTOR activity falls, cells turn on autophagy, a recycling process where damaged proteins and worn-out cellular components get broken down and repurposed. A small human trial found that a six-day FMD improved markers of autophagic flux along with fasting glucose and insulin resistance, though the researchers noted that larger studies are needed to confirm those results.⁴

The Regeneration Phase

Perhaps the most striking aspect of the FMD is what happens after the fasting period ends. The restriction phase shrinks certain tissues and depletes old or damaged cells. Refeeding then acts as a growth signal, and progenitor and stem cells proliferate to rebuild what was lost. In mice, four days on the FMD shrank multiple organ systems, and the subsequent return to normal eating triggered an increase in stem and progenitor cells and a regenerative wave across those systems.⁵

This “break it down, build it back” cycle has been studied in specific tissues. In the pancreas, for instance, the FMD reduced the proportion of insulin-producing beta cells by about 35 percent during the fasting phase. Within three days of refeeding, beta cell numbers returned to baseline, and the cells remained in a more proliferative state than before.⁶ That finding is especially relevant for diabetes, where beta cell loss is a core problem. It suggests the FMD does not just temporarily improve blood sugar numbers but may help the body rebuild the cellular machinery that produces insulin.

Type 2 Diabetes and Metabolic Health

The strongest human evidence for the FMD so far comes from metabolic health research. A 12-month randomized controlled trial integrated monthly FMD cycles into primary care for people with type 2 diabetes. Compared with usual care alone, participants using the FMD lost about 3.6 kilograms more, lowered their HbA1c (a measure of long-term blood sugar control), and reduced their need for diabetes medication. Glycemic management improved in roughly half of FMD participants versus only 8 percent of controls, and it deteriorated in about a quarter of FMD participants versus nearly 60 percent of controls.⁷ Imaging from the same program showed that the FMD specifically reduced deep abdominal fat (both around the organs and under the skin) while leaving abdominal muscle mass unchanged.⁸

That selective fat loss without muscle loss is a meaningful distinction. Many calorie-restricted diets cause you to lose lean tissue alongside fat, which can slow your metabolism and undermine long-term weight management. A trial comparing the FMD to standard continuous calorie restriction in women with obesity found that although total weight loss was similar between the two groups, only the FMD group showed favorable changes in fat mass relative to muscle mass. The continuous restriction group also had a greater reduction in basal metabolic rate, and their levels of hunger-related hormones (ghrelin and neuropeptide Y) rose significantly, suggesting the body was fighting back harder against the restriction.⁹

Blood Pressure and Heart Disease Risk

A 2025 systematic review and meta-analysis pooling data from randomized trials found that the FMD significantly reduced systolic blood pressure by about 4 mmHg and diastolic blood pressure by about 2 mmHg. Effects on cholesterol fractions and triglycerides, however, were not significant in the pooled analysis, and the results for those lipid markers were highly variable across studies.¹⁰ An earlier crossover trial found more encouraging lipid results, but only in participants who were already at elevated risk: those with higher baseline levels of body mass, blood pressure, glucose, triglycerides, or cholesterol saw more pronounced improvements after three FMD cycles than participants who started out healthy.¹¹

The pattern across studies is consistent: the FMD tends to help most where help is most needed. If your metabolic markers are already in a healthy range, the changes from three to five cycles are modest. If you are carrying excess visceral fat, have creeping blood sugar, or have borderline blood pressure, the effects are more pronounced. That makes sense from a biological standpoint. The signaling pathways the FMD targets (insulin, IGF-1, mTOR) are overactive in metabolic disease and functioning normally in healthy people, so there is more room for correction.

Biological Age

One of the more attention-grabbing findings involves biological age, a composite score based on blood biomarkers that predicts disease risk and mortality better than calendar age alone. Secondary analysis of two separate clinical trials found that three FMD cycles were associated with a median decrease of about 2.5 years in biological age, and the effect was independent of weight loss.¹² Pooling participants from both trials brought the median reduction to 2.6 years. A conference review summarizing the latest research confirmed that the 2.5-year reduction was replicated across those two independent clinical trials.¹³

It is worth being clear-eyed about what this means. Biological age clocks are predictive tools, not direct measurements of how old your organs are. The FMD improved the specific blood markers that feed into the clock (insulin resistance markers, inflammatory markers, liver-function values), and the clock score went down. Whether that translates into living longer is a question no short-term trial can answer. Still, the consistency of the result across two separate groups is encouraging, and it aligns with the broader metabolic improvements seen in other FMD trials.

Brain Health and Cognitive Function

In aging mice, FMD cycles promoted the growth of new neurons in the hippocampus (the brain region central to memory), reduced IGF-1 signaling in the brain, and improved performance on tests of working memory, object recognition, and spatial learning compared to mice on a normal diet.¹⁴ In Alzheimer’s disease mouse models, bimonthly FMD cycles reduced the hallmark protein deposits (amyloid-beta plaques and hyperphosphorylated tau) in the hippocampus, increased neural stem cell production, and decreased neuroinflammation. Behaviorally, these mice showed improved visual attention, working memory, and spatial memory, along with reduced anxiety-like behavior.¹⁵

No large human trials have tested the FMD specifically for dementia prevention yet. The animal work is compelling because it shows effects on multiple disease mechanisms at once, not just one target, but translating mouse brain studies to human clinical outcomes is a notoriously uncertain leap. The optimal number of cycles and the age at which to start remain open questions.¹⁶

Cancer and the Idea of Differential Stress

The FMD’s relevance to cancer hinges on a concept called differential stress resistance. Normal, healthy cells respond to fasting signals by shifting into a protective mode: they slow down growth, ramp up DNA repair, and become more resistant to toxic insults. Cancer cells, by contrast, are driven by mutations that lock their growth pathways in the “on” position. They cannot downshift the way healthy cells can, which makes them more vulnerable to chemotherapy or other stressors when the body’s growth signals are withdrawn.¹⁷ The FMD creates the low-insulin, low-IGF-1 environment that widens this gap between healthy and cancerous cells. Several early-phase clinical trials have combined FMD cycles with standard chemotherapy regimens, and the approach is considered safer and more tolerable for patients than water-only fasting or chronic dietary restriction.²

This remains an early area of research in humans. The preclinical logic is sound and well-supported, but whether the FMD meaningfully improves survival or treatment response in human cancer patients is still being tested in ongoing trials.

Autoimmune Conditions and Gut Health

The FMD has shown promise in autoimmune and inflammatory disease models. In a mouse model of multiple sclerosis, periodic three-day FMD cycles reduced disease severity in all animals and completely reversed symptoms in 20 percent of them. The improvements were linked to suppression of pro-inflammatory immune cells and, remarkably, to regeneration of oligodendrocyte precursor cells, the cells that rebuild the myelin insulation around nerve fibers that MS destroys.¹⁸

In models of inflammatory bowel disease, FMD cycles reduced intestinal inflammation, increased the number of intestinal stem cells, and promoted shifts in the gut microbiome toward protective bacterial populations. Notably, transplanting the gut bacteria from FMD-treated mice into untreated mice with colitis was enough to reduce inflammation and restore colon length, suggesting the microbiome changes are not just a byproduct but an active contributor to the benefit.¹⁹ Separately, intermittent FMD administration in diabetic mice restructured the gut microbiome, increasing certain genera associated with metabolic health while reducing others linked to inflammation. Those bacterial shifts correlated with improvements in fasting blood glucose.²⁰

Muscle and Physical Performance

A common worry about any fasting protocol is whether it costs you muscle or impairs your ability to train. A randomized controlled trial in young, healthy men found that completing an FMD cycle did not reduce any measured neuromuscular parameter of force production and did not decrease muscle volume. The researchers concluded that the FMD could be safely adopted by strength athletes without detrimental effects.²¹ Combined with the diabetes trial data showing preserved abdominal muscle mass over 12 months of monthly FMD cycles, the picture so far is reassuring: the FMD appears to preferentially burn fat while leaving lean tissue intact.

That said, you would probably want to avoid scheduling a competition or a peak training week during the five-day restriction phase itself. Even if muscle is preserved, calorie intake that low will limit your ability to perform at your best or recover from high-intensity sessions. The practical approach most researchers suggest is to schedule FMD cycles during lighter training periods and resume normal fueling immediately after.

How the FMD Differs From Other Fasting Approaches

The FMD sits in a distinct niche among dietary interventions that involve food restriction. Time-restricted eating (the popular “intermittent fasting” patterns like 16:8) limits when you eat each day but does not necessarily reduce total calories or change macronutrient composition enough to substantially lower IGF-1 and activate the deep stress-response pathways the FMD targets. Water-only fasting does activate those pathways powerfully, but it is harder to sustain, carries more medical risk (particularly for people on medication), and in at least one direct comparison in the inflammatory bowel disease model, water-only fasting increased some regenerative markers but failed to reverse intestinal damage the way the FMD did.¹⁹ Chronic calorie restriction, meanwhile, can deliver some overlapping metabolic benefits but tends to cause more muscle loss, greater metabolic adaptation, and stronger hunger-hormone rebound than a periodic FMD approach.

The FMD’s advantage is that the restriction is temporary and cyclical. You endure five difficult days, then eat normally for three or four weeks. Because the fasting period is short relative to the recovery period, muscle mass is preserved, metabolic rate does not tank, and compliance appears to be more sustainable than daily restriction. The regenerative refeeding phase, which continuous diets lack entirely, adds a biological dimension that goes beyond simple calorie math.

Who Should Be Cautious

The FMD is not appropriate for everyone. People who are underweight, pregnant, or breastfeeding should avoid it. Anyone with a history of eating disorders should be cautious about any protocol involving severe calorie restriction, even if temporary. If you take medication for diabetes or blood pressure, the metabolic shifts during the fasting days can alter your drug requirements quickly, and you should only attempt the FMD under medical supervision. The diabetes trial that showed such promising results was conducted within a primary care setting with regular monitoring, not as a self-directed experiment.

Children, adolescents, and adults over 70 are generally excluded from FMD research, and the safety profile in those groups is not established. Longo himself has said that people over 65 or 70 should use shorter or less restrictive versions to avoid excessive protein depletion in a population already prone to sarcopenia. If you have any chronic illness, the right move is to discuss the FMD with your doctor before trying it, not because the diet is inherently dangerous but because the metabolic changes it triggers interact with medications and pre-existing conditions in ways that need monitoring.

Open Questions in the Field

For all the promising data, the FMD field still has significant gaps. Most of the mechanistic work, including the regeneration, neurogenesis, and autoimmunity findings, comes from animal models. The human trials that exist are relatively small and short-term. The 12-month diabetes trial is the longest and most rigorous to date, but even it involved only a few hundred participants. No one has yet run a large, multi-year trial tracking hard endpoints like heart attacks, cancer diagnoses, or dementia onset.

The optimal frequency and duration of cycles also remain unsettled. Some studies use monthly cycles, others bimonthly, and the commercial protocol recommends anywhere from once a month to a few times per year depending on your metabolic health. Whether more frequent cycles deliver proportionally greater benefit, or whether there is a ceiling (or even a point of diminishing returns where too-frequent restriction becomes counterproductive), is simply not known yet. The gut microbiome findings are tantalizing but almost entirely from mice, and translating microbial shifts in rodents to clinical benefit in humans has proven unreliable across many fields of research. For now, the FMD has the strongest evidence base for metabolic syndrome, prediabetes, and type 2 diabetes, and the most speculative evidence for neurodegeneration and cancer, where the biological rationale is strong but the human data are still catching up.